Outcomes and treatment patterns of adding a third agent to 2 OADS in patients with type 2 diabetes

Social Sciences

• chronic illness 86%
• drug 59%
• persistence 38%
• Blood glucose 17%
• physician 16%
• drug therapy 15%
• health care 15%
• treatment decisions 14%
• comorbidity 13%
• costs 12%
• Health Care Providers 11%
• medication 9%
• evidence 4%

Chemical Compounds

• Glucagon-Like Peptide-1 Receptor Agonist 100%
• Oral Antidiabetic Agent 94%
• Insulin Derivative 89%
• Reduction 13%
• Antidiabetic Agent 8%
• Glucose 5%

Medicine & Life Sciences

• Type 2 Diabetes Mellitus 65%
• Glucagon-Like Peptide-1 Receptor 37%
• Hypoglycemic Agents 35%
• Insulin 34%
• Therapeutics 8%
• Health Care Costs 7%
• Physicians 5%
• Injections 4%
• Proxy 4%
• Hypoglycemia 4%
• Health Personnel 3%
• Blood Glucose 3%
• Life Style 3%
• Comorbidity 3%
• Retrospective Studies 2%
• Drug Therapy 2%